Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
CLINIMIX E 4.25/25 is a sterile, nonpyrogenic, hypertonic solution of amino acids and dextrose used for parenteral nutrition. Dextrose provides a source of calories and is metabolized to carbon dioxide and water, yielding energy. Amino acids provide building blocks for protein synthesis, tissue repair, and maintenance of nitrogen balance.
Travasol 2.75% with electrolytes in dextrose 15% is a parenteral nutrition formulation. It provides amino acids for protein synthesis, dextrose for caloric energy, and electrolytes for maintaining homeostasis. Dextrose stimulates insulin release and provides glucose for cellular metabolism. Amino acids are utilized for tissue repair and nitrogen balance. Electrolytes maintain acid-base balance, neuromuscular function, and enzymatic processes.
Parenteral nutrition for patients requiring caloric and amino acid intake when oral or enteral nutrition is not possible, insufficient, or contraindicated,Off-label: May be used in specific metabolic disorders requiring controlled amino acid and dextrose delivery
Parenteral nutrition for patients who cannot obtain adequate nutrition orally or enterally,Off-label: Adjunctive therapy in catabolic states (e.g., burns, trauma, sepsis)
Intravenous infusion; dose is individualized based on patient's metabolic needs, weight, and clinical status. Typical adult dose: 1-2 L/day of CLINIMIX E 4.25/25 providing 4.25% amino acids and 25% dextrose. Rate of administration should not exceed 4 mg/kg/min of dextrose equivalent.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER is a total parenteral nutrition (TPN) solution. Adult dosing is based on caloric and protein needs: typically 1-2 L/day intravenously, providing 15% dextrose (150 g/L) and 2.75% amino acids (27.5 g/L). Infusion rate initially 1.5-2 m L/min, adjusted to meet metabolic requirements.
Not applicable as a single drug. The components have varied half-lives: amino acids have a plasma half-life of minutes to hours (e.g., alanine ~15 min); dextrose has a half-life of 1.5-2 hours under normal conditions, prolonged in renal impairment or hyperglycemia. Clinical context: in total parenteral nutrition, continuous infusion maintains steady state. No terminal half-life for the mixture.
Not applicable (mixture of nutrients with endogenous clearance). Glucose: ~1-2 h; amino acids: ~0.5-2 h; electrolytes: vary.
For GFR 30-59 m L/min: reduce volume by 25-50%; monitor electrolytes. For GFR 15-29 m L/min: reduce volume by 50-75%; avoid if severe renal impairment. For GFR <15 m L/min: contraindicated unless on renal replacement therapy; use with caution and adjust electrolytes.
In renal impairment (GFR <30 m L/min): restrict fluid and electrolytes; use specialized amino acid formulations (e.g., essential amino acid solutions). Dextrose content may cause hyperglycemia; monitor glucose. Reduce volume and electrolytes as needed. For non-dialysis patients, avoid unless specific benefits outweigh risks.
CLINIMIX E 4.25/25 contains amino acids, dextrose, electrolytes, and calcium. No teratogenic effects have been reported in animal studies. In first trimester: limited human data, but no evidence of malformations. Second and third trimesters: no known fetal risks. However, hyperglycemia from dextrose may cause fetal macrosomia and neonatal hypoglycemia if maternal glucose control is poor.
This formulation provides 4.25% amino acids and 25% dextrose with electrolytes and calcium for total parenteral nutrition. Contains sulfite-free preparation; confirm patient's sulfite allergy status. Monitor serum electrolytes, blood glucose, and liver function tests; adjust infusion rate to avoid refeeding syndrome in malnourished patients.
Contains 2.75% amino acids, 15% dextrose, and electrolytes. Ensure central line access for high osmolality (approx. 1450 m Osm/L). Monitor serum electrolytes, glucose, and fluid status. Avoid in patients with severe metabolic alkalosis or anuria. Contains sulfite, may cause allergic reactions in asthmatics.
No interactions on record
No interactions on record
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER are distinct pharmacological agents. CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER belongs to the Parenteral Nutrition Solution class and is primarily used for Parenteral nutrition for patients requiring caloric and amino acid intake when oral or enteral nutrition is not possible, insufficient, or contraindicatedOff-label: May be used in specific metabolic disorders requiring controlled amino acid and dextrose delivery. TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER belongs to the Parenteral Nutrition Solution class and is primarily used for Parenteral nutrition for patients who cannot obtain adequate nutrition orally or enterallyOff-label: Adjunctive therapy in catabolic states (e.g., burns, trauma, sepsis). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER carries a safety status of Category C, whereas TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Dextrose undergoes glycolysis and oxidation via the citric acid cycle. Amino acids are deaminated and metabolized via ureagenesis and gluconeogenesis.
Metabolized via amino acid oxidation and gluconeogenesis in the liver and kidneys. Dextrose undergoes glycolysis and oxidative phosphorylation. Electrolytes are not metabolized but excreted or retained as needed.
The components of CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER are nutrients and electrolytes that are metabolized or excreted via normal physiological pathways. Amino acids are deaminated, with nitrogen excreted primarily as urea in urine (about 90%) and a small amount in feces. Dextrose is metabolized to carbon dioxide and water, with excess exhaled as CO2 (approximately 50-70% of glucose carbon) or excreted in urine if renal threshold exceeded. Electrolytes are excreted renally in proportion to intake and homeostasis. No single excretion route percentage applies to the mixture; for amino acids, renal excretion of metabolites (urea) accounts for >90% of nitrogen elimination.
Renal: 100% (as glucose, amino acids, and electrolytes). Biliary/fecal: negligible.
Amino acids: variable, generally low (0-30%) bound to albumin and other plasma proteins. Dextrose: negligible protein binding. Electrolytes: calcium is ~40-50% bound to albumin and other proteins; magnesium ~30%; phosphate ~10-20%; others minimal. Overall, component-specific.
None for components. Amino acids: minimal (<10%).
Not applicable as a single entity. Amino acids distribute into total body water (~0.5-0.6 L/kg). Dextrose distributes into extracellular fluid (~0.2 L/kg) initially, then intracellularly. Electrolytes distribute according to their physiological compartments. No meaningful Vd for the mixture.
Not applicable as a mixture; individual components distribute into total body water (0.6 L/kg) or extracellular fluid (0.2 L/kg).
Intravenous: 100% bioavailability as it is administered directly into the bloodstream. Not applicable to oral or other routes.
Intravenous: 100% (only route).
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce amino acid dose by 50%; monitor ammonia. Child-Pugh Class C: avoid due to risk of hepatic encephalopathy; alternative nutrition may be needed.
In hepatic impairment (Child-Pugh class B or C): monitor for encephalopathy; amino acid load may precipitate hepatic encephalopathy. Use lower protein intake (0.6-0.8 g/kg/day) or branched-chain amino acid enriched solutions. Dextrose may exacerbate hyperglycemia; adjust insulin as needed.
Dose based on weight (kg) and caloric needs. Typical: 10-15 m L/kg/day initially, titrate to 20-30 m L/kg/day. Maximum dextrose infusion rate: 0.5 g/kg/hr for neonates, 1 g/kg/hr for older children. Use with caution in low birth weight infants.
Weight-based: neonates 1-3 g/kg/day amino acids, up to 15 g/kg/day dextrose, titrated. Infants and children: 1-2 g/kg/day amino acids, 10-20% dextrose at 1-2 m L/kg/hour. Adjust electrolytes per serum levels. Use age-specific formulations; monitor growth and metabolic parameters.
Elderly patients often require lower doses due to decreased renal function; start at lower infusion rates (e.g., 1-2 m L/kg/hr). Monitor fluid balance, electrolytes, and renal function closely. Dose adjustment based on GFR is recommended.
Elderly: start at lower volume (0.5-1 L/day) due to reduced renal function and fluid reserve. Monitor glucose and electrolytes closely; dextrose load may require insulin. Amino acid dosing per protein requirements (1-1.2 g/kg/day if no renal impairment). Adjust for comorbidities.
Not for intravenous infusion unless admixed with appropriate electrolytes and vitamins. Do not administer simultaneously with blood through the same infusion site because of risk of pseudoagglutination. Use with caution in patients with severe hepatic or renal disease.
Not for intravenous injection as a sole source of nutrition. Contains aluminum that may be toxic. Use with caution in renal impairment due to aluminum accumulation. Do not administer unless solution is clear and container undamaged.
Do not administer with any oral food or enteral nutrition unless specifically ordered; interactions depend on individual patient condition. Concomitant use of oral hypoglycemic agents may require dose adjustment due to dextrose content.
None; parenteral nutrition bypasses gastrointestinal tract. However, monitor oral intake if transitioning to enteral nutrition.
No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Parenteral nutrition is essential in certain conditions; use only if clearly needed. Potential fetal risks include metabolic disturbances (e.g., hyperglycemia, electrolyte imbalances) associated with maternal administration of dextrose and electrolytes, which may affect fetal homeostasis. However, no specific teratogenic effects have been documented.
Components are endogenous substances normally found in breast milk. Dextrose and amino acids are present in milk; no adverse effects expected. M/P ratio not established. Safe to use during breastfeeding when clinically indicated.
It is not known whether components of this solution are excreted in human milk. No M/P ratio available. Caution should be exercised when administered to a breastfeeding woman. The high dextrose content may affect maternal glucose levels, indirectly influencing milk composition. Consider the benefits of breastfeeding and the importance of the drug to the mother.
Pregnancy increases plasma volume and renal clearance, but dosing adjustments are not typically required. Monitor glucose and electrolyte levels to avoid hyperglycemia or electrolyte imbalances. Use standard parenteral nutrition guidelines with close monitoring.
Pharmacokinetic changes in pregnancy may require dose adjustments: increased plasma volume and glomerular filtration rate may alter electrolyte and fluid balance; increased insulin resistance may necessitate modifications in dextrose delivery. Monitor glycemic control and adjust dextrose infusion rate accordingly. Electrolyte requirements may change; adjust based on serum levels. No specific dosing guidelines are established; individualize based on maternal clinical status and laboratory parameters.
This medication is given intravenously to provide nutrition when you cannot eat.,Report any signs of infection at the IV site: redness, swelling, pain, or fever.,You may need regular blood tests to monitor your blood sugar, electrolyte levels, and liver function.,Do not suddenly stop the infusion without consulting your healthcare provider.,Inform your healthcare provider if you have diabetes, as this solution contains dextrose (sugar).
This solution provides nutrition and fluids directly into your vein.,Your blood sugar and electrolyte levels will be monitored regularly.,Report any signs of infection at the IV site like redness, swelling, or warmth.,Do not stop or adjust the infusion rate yourself.